Contraceptive Technology Update – November 1, 2016
November 1, 2016
View Issues
-
LARC Options Expand With New Intrauterine Device
Family planning clinicians are adding another choice to the expanding list of long-acting reversible contraceptive options with the September 2016 FDA approval of the Kyleena 19.5 mg levonorgestrel IUD from Whippany, NJ-based Bayer HealthCare Pharmaceuticals. The new IUD is available as of October 2016 by prescription only.
-
Deaths From Ovarian Cancer Fall Worldwide Due to Oral Contraceptive Use, Data Show
Deaths from ovarian cancer fell worldwide between 2002 and 2012 and are predicted to continue to decline through 2020 in the United States, European Union, and, to a lesser extent, in Japan, according to newly published research. The primary reason is the use of oral contraceptives and the long-term protection against ovarian cancer that they provide, say researchers.
-
WHO Updates STI Treatment Guidance Due to Growing Antibiotic Resistance
The World Health Organization has issued new guidelines for the treatment of chlamydia, gonorrhea, and syphilis in response to the growing threat of antibiotic resistance. According to the international health organization, each year, 131 million people are infected with chlamydia, 78 million are infected with gonorrhea, and 5.6 million are infected with syphilis.
-
Research Eyes Hormonal Contraceptive Use And Impact on Vitamin D Levels
Women risk having their vitamin D levels fall when they stop using birth control pills or other contraceptives containing estrogen, new research indicates. This finding has clinical implications when counseling women who are planning to conceive and identifying women who may be at risk of deficiency.
-
Federal Agencies Issue More Family Planning Rules
Federal agencies are continuing to issue regulations and guidance with a sense of urgency, and, in several cases, the implications for family planning care may be profound.
-
Updating the Guidance On Women’s Preventive Services
A coalition of national health professional organizations, as well as women’s health consumer and patient advocates, are updating the federal Women’s Preventive Services Guidelines. If the recommendations are adopted by the Department of Health and Human Services’ Health Resources and Services Administration, it will help ensure that women receive a comprehensive set of preventive services without having to pay a copayment, co-insurance, or deductible.